FDA Approved for RRMM: Sarclisa (isatuximab-irfc) + Kyprolis (Carfilzomib) and Dexamethasone (IKd)
On March 31, 2021, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, sanofi-aventis U.S. LLC) in combination with...
Dec 10, 2021
352
RRMM:Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Pomalidomide (Pomalyst) & Dexamethasone
FDA approved for RRMM: Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Pomalidomide (Pomalyst) and Dexamethasone Relapsed &...
Dec 9, 2021
439
FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj(Darzalex Faspro) + Kyprolis & Dexamethasone
FDA Approved for RRMM: Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Kyprolis & Dexamethasone FDA approves Darzalex Faspro,...
Dec 2, 2021
216
Abecma: CART Cell Therapy -FDA Approves First Cell-Based Gene Therapy for Adult Patients with RRMM
For Immediate Release: March 27, 2021: The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene...
Dec 1, 2021
370
FDA Approved for RRMM: Xpovio (selinexor) tablets + Velcade (Bortezomib) and Dexamethasone
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with...
Dec 18, 2020
172
FDA Approved for RRMM: Sarclisa (isatuximab-irfc) + Pomalyst (Pomalidomide) and Dexamethasone (IPd)
On March 2, 2020, the Food and Drug Administration approved isatuximab-irfc (SARCLISA, sanofi-aventis U.S. LLC) in combination with...
Dec 10, 2020
145